Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment
Joint Authors
Martínez-Cáceres, Eva
Quirant-Sánchez, Bibiana
Presas-Rodriguez, Silvia
Mansilla, María José
Teniente-Serra, Aina
Hervás-García, José V.
Brieva, Luis
Moral-Torres, Ester
Cano, Antonio
Munteis, Elvira
Navarro-Barriuso, Juan
Ramo-Tello, Cristina
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-06-26
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients have not been identified yet.
Here, we analyzed the immune phenotype of T lymphocyte subpopulations in peripheral blood samples from 66 RRMS patients under DMF (n=22) or fingolimod (n=44) treatment, by flow cytometry.
A correlation study between the percentage and absolute cell number of each lymphocyte subpopulation with the presence of relapses or new MRI lesions during 12-month follow-up was performed.
Patients who had undergone relapses showed at baseline higher percentage of Th1CM cells (relapsed: 11.60±4.17%vs.
nonrelapsed: 9.25±3.17%, p<0.05) and Th1Th17CM cells (relapsed: 15.65±6.15%vs.
nonrelapsed: 10.14±4.05%, p<0.01) before initiating DMF or fingolimod treatment.
Kaplan-Meier analysis revealed that patients with Th1Th17CM (CD4+CCR7+CD45RA-CCR6+CXCR3+) cells>11.48% had a 50% relapse-free survival compared to patients with Th1Th17CMcells<11.48% whose relapse-free survival was 88% (p=0.013, log-rank test).
Additionally, a high percentage of Th1Th17CM cells was also found in patients with MRI activity (MRI activity: 14.02±5.87%vs.
no MRI activity: 9.82±4.06%, p<0.01).
Our results suggest that the percentage of Th1Th17CM lymphocytes at baseline is a predictive biomarker of activity during the first 12 months of treatment, regardless of the treatment.
American Psychological Association (APA)
Quirant-Sánchez, Bibiana& Presas-Rodriguez, Silvia& Mansilla, María José& Teniente-Serra, Aina& Hervás-García, José V.& Brieva, Luis…[et al.]. 2019. Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment. Mediators of Inflammation،Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1193382
Modern Language Association (MLA)
Quirant-Sánchez, Bibiana…[et al.]. Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment. Mediators of Inflammation No. 2019 (2019), pp.1-9.
https://search.emarefa.net/detail/BIM-1193382
American Medical Association (AMA)
Quirant-Sánchez, Bibiana& Presas-Rodriguez, Silvia& Mansilla, María José& Teniente-Serra, Aina& Hervás-García, José V.& Brieva, Luis…[et al.]. Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment. Mediators of Inflammation. 2019. Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1193382
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1193382